Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amicus Therapeutics (FOLD) Operating Leases (2019 - 2025)

Historic Operating Leases for Amicus Therapeutics (FOLD) over the last 7 years, with Q3 2025 value amounting to $42.2 million.

  • Amicus Therapeutics' Operating Leases fell 954.25% to $42.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $42.2 million, marking a year-over-year decrease of 954.25%. This contributed to the annual value of $45.1 million for FY2024, which is 2119.37% down from last year.
  • Latest data reveals that Amicus Therapeutics reported Operating Leases of $42.2 million as of Q3 2025, which was down 954.25% from $43.4 million recorded in Q2 2025.
  • Over the past 5 years, Amicus Therapeutics' Operating Leases peaked at $60.1 million during Q4 2022, and registered a low of $42.2 million during Q3 2025.
  • Its 5-year average for Operating Leases is $48.8 million, with a median of $47.8 million in 2024.
  • In the last 5 years, Amicus Therapeutics' Operating Leases surged by 1958.16% in 2022 and then tumbled by 2119.37% in 2024.
  • Over the past 5 years, Amicus Therapeutics' Operating Leases (Quarter) stood at $50.8 million in 2021, then grew by 18.43% to $60.1 million in 2022, then decreased by 4.87% to $57.2 million in 2023, then fell by 21.19% to $45.1 million in 2024, then dropped by 6.44% to $42.2 million in 2025.
  • Its Operating Leases was $42.2 million in Q3 2025, compared to $43.4 million in Q2 2025 and $44.2 million in Q1 2025.